TV News LIES

Sunday, Apr 26th

Last update07:43:00 PM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Diet Pepsi dropping aspartame on customer concerns

Diet PepsiPepsiCo says it's dropping aspartame from Diet Pepsi in response to customer feedback and replacing it...

Why The FDA Has Never Looked At Some Of The Additives In Our Food

food additivesCompanies have added thousands of ingredients to foods with little to no government oversight. That's thanks...

Blue Bell expands recall to all of its products

Wisteria outbreakBrenham-based Blue Bell Creameries is pulling all of its products from the shelves after more ice...

Georgia governor signs bill to legalize medical marijuana

Nathan DealGeorgia Gov. Nathan Deal, signed a bill Thursday legalizing medical marijuana in the state, but questions...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!